Deutsche Bank’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Deutsche Bank’s Portfolio SGTX Stock Details SGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,332	Closed	-$25K	–	4414
2022 Q1	$25K	Buy	1,332 +621	+87%	+$13.8K	﹤0.01%	4024
2021 Q4	$25K	Sell	711 -751	-51%	-$42.7K	﹤0.01%	4105
2021 Q3	$107K	Buy	1,462 +1,100	+304%	+$84.7K	﹤0.01%	3882
2021 Q2	$51K	Sell	362 -850	-70%	-$149K	﹤0.01%	4309
2021 Q1	$352K	Buy	+1,212	New	+$482K	﹤0.01%	3323

Other funds holding SGTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank's SGTX Position: Q2 2022 in Review

Deutsche Bank sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2022, closing a stake of 1,332 shares — an estimated $25K sold.

Deutsche Bank first reported a position in SGTX in Q1 2021 and held it in 5 quarters. The position peaked at $352K in Q1 2021. 37 funds tracked by Wall St. Rank hold SGTX as of Q2 2022.

Deutsche Bank reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Deutsche Bank sold 1,332 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $25K.
Deutsche Bank first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
Deutsche Bank's Sigilon Therapeutics, Inc. Common Stock position peaked at $352K in Q1 2021.
37 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Deutsche Bank's 13F filing for Q2 2022, filed 11 Aug 2022.